Figure 2.

Linear associations of baseline (off-treatment) log urinary 11-dehydro-thromboxane B₂ with the outcomes (Serious vascular event or revascularization [A], Major bleed [B] and Any cancer [C]) incrementally adjusting for predictors of log urinary 11-dehydro-thromboxane B₂. A stepwise selection model was used to find baseline predictors of log urinary 11-dehydro-thromboxane B₂ in both treatment arms. The basic adjustors age group, sex, urine volume assayed, and treatment allocation were forced into the model. The association of log urinary 11-dehydro-thromboxane B₂ with outcome was then modelled by adjusting for the predictors of log urinary 11-dehydro-thromboxane B₂, with the factors added incrementally in the order they were selected in the prediction model. *SD of log urinary 11-dehydro-thromboxane B₂ is 0.622. Hence, 1 SD corresponds to an exp(0.622) = 1.862 fold higher urinary 11-dehydro-thromboxane B₂. CI, confidence interval; n, number of events; SD, standard deviation; U-TXM, urinary 11-dehydro-thromboxane B₂